ANO2 and myeloid sarcoma: More recently the same group was able to establish molecular mimicry between ANO2 (AA 140-149) and EBNA1 (AA 431 – 440) and confirmed an increased MS risk for ANO2-seropositive individuals, HLA-DRB1*15:01 carriage, and high anti-EBNA1 antibody levels (34).